Johnson & Johnson Reports Earnings, Notably Lowers EOY Outlook
Johnson & Johnson reported a miss on its Q1 earnings just shy of analyst expectations. The pharmaceutical giant also noted that it has an excess of COVID-19 vaccines and that it will be lowering its end-of-year earnings outlook for 2022.
Sean Klitzner, showrunner and co-creator of Beast Games, previews the Feb. 25 finale packed with bigger stunts, wild twists, and the highest stakes yet.
Bob Sallmann, CFO of McGraw Hill, breaks down the quarter’s standout performance, digital expansion, and how AI tools are driving education innovation.
Daniel Desrochers, International Trade Reporter at POLITICO, joins us to break down the ruling, the billions at stake, and what it means for consumers.
NeuralAI Technologies' talks about its neuromorphic hardware powering next-gen AI applications. Plus, how High Frequency Highway is using AI for well-being.
